Literature DB >> 9415645

Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjögren's syndrome.

G Valesini1, R Priori, D Bavoillot, J Osborn, M G Danieli, N Del Papa, R Gerli, M Pietrogrande, M G Sabbadini, F Silvestris, L Valsecchi.   

Abstract

OBJECTIVE: To assess the incidence of non-Hodgkin's lymphoma (NHL) and estimate the relative risk (RR) of developing lymphoproliferative complications in a large population of Italian patients with Sjögren's syndrome (SS) and to ascertain if any difference exists between the north and centre-south of Italy.
METHODS: Differential relative risks of NHL were obtained by comparing the number of observed cases with cases identified on the basis of age-sex-time specific incidence rates extracted from regional cancer registries.
RESULTS: Among the 331 patients with SS studied, 9 cases of NHL occurred, while no lymphoid malignancy appeared in patients with overlapping connective tissue disease (secondary SS) or in males with primary SS. As the number of NHL cases identified on the basis of the rate in the cancer registries would have been 0.27, the RR is 33.3 (p < 0.001). The incidence rate of NHL in Italian patients with SS is about 5.1/1000 person-years. 5.4/1000 per year in the north of the country and 4.8/1000 per year in the centre-south. The relative risks are, respectively, 34.7 and 32.5.
CONCLUSION: Italian patients with primary SS have increased risk of developing NHL. In this group, the absence of a significant difference between the north and the centre-south of Italy contrasts with the higher incidence of NHL in the general population of northern regions and strengthens the direct connection between primary SS and NHL.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9415645

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  15 in total

Review 1.  Imaging of the pulmonary manifestations of systemic disease.

Authors:  A G Rockall; D Rickards; P J Shaw
Journal:  Postgrad Med J       Date:  2001-10       Impact factor: 2.401

Review 2.  Immunopathogenesis of Sjögren's syndrome.

Authors:  Andrea T Borchers; Stanley M Naguwa; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2003-08       Impact factor: 8.667

3.  Survival analysis of patients with Sjögren's syndrome in Turkey: a tertiary hospital-based study.

Authors:  Veli Yazisiz; Mesut Göçer; Funda Erbasan; İsmail Uçar; Bengisu Aslan; Şuayp Oygen; Edip Gökalp Gök; Mustafa Ender Terzioğlu
Journal:  Clin Rheumatol       Date:  2019-09-25       Impact factor: 2.980

Review 4.  Primary Sjögren's syndrome: clinical phenotypes, outcome and the development of biomarkers.

Authors:  Andreas V Goules; Athanasios G Tzioufas
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

Review 5.  Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome.

Authors:  Michael Voulgarelis; Athanasios G Tzioufas
Journal:  Nat Rev Rheumatol       Date:  2010-08-03       Impact factor: 20.543

Review 6.  Advances in understanding the pathogenesis of primary Sjögren's syndrome.

Authors:  Gaëtane Nocturne; Xavier Mariette
Journal:  Nat Rev Rheumatol       Date:  2013-07-16       Impact factor: 20.543

Review 7.  Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients.

Authors:  Michael Voulgarelis; Fotini N Skopouli
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

8.  [Recurrent abcesses of the parotid gland in Sjögren's syndrome].

Authors:  A Knopf; A Pickhard; T Stark; S Schulz; E Q Scherer
Journal:  HNO       Date:  2009-09       Impact factor: 1.284

Review 9.  Identification of lymphoma predictors in patients with primary Sjögren's syndrome: a systematic literature review and meta-analysis.

Authors:  Maria B Nishishinya; Claudia A Pereda; Santiago Muñoz-Fernández; José M Pego-Reigosa; Iñigo Rúa-Figueroa; José-Luis Andreu; Mónica Fernández-Castro; José Rosas; Estibaliz Loza Santamaría
Journal:  Rheumatol Int       Date:  2014-06-05       Impact factor: 2.631

Review 10.  Lymphoproliferation in autoimmunity and Sjögren's syndrome.

Authors:  Michalis Voulgarelis; Haralampos M Moutsopoulos
Journal:  Curr Rheumatol Rep       Date:  2003-08       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.